Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA + GD2 CAR T cells
- Development stage
- Unknown
- Lead developer
- Clifford Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PSMA + GD2 CAR T cells is an investigational fourth-generation dual-target chimeric antigen receptor T cell (CAR-T) therapy developed by Guangdong Clifford Hospital. It is designed for the treatment of relapsed or refractory grade IV glioma. The therapy involves the co-administration of two distinct CAR-T cell products: one targeting Prostate-Specific Membrane Antigen (PSMA) and another targeting Disialoganglioside (GD2). By targeting two different antigens commonly expressed on glioma cells and within the tumor microenvironment, the therapy aims to overcome tumor heterogeneity and reduce the risk of antigen escape. In early-phase clinical studies, the treatment has demonstrated preliminary efficacy with a manageable safety profile, achieving an overall response rate of 50% in a small cohort of patients.
- Other names
- PSMA+GD2 dual-target CAR T cellsPSMA/GD2 CAR-T
02
Targets
GD2
Beyond the preview
Go deeper on PSMA + GD2 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA + GD2 CAR T cells.